Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves

This publication has 22 references indexed in Scilit:

• Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma
  Annals of Allergy, Asthma & Immunology, 2002
• Psychopathology in Patients with Severe Asthma Is Associated with Increased Health Care Utilization
  American Journal of Respiratory and Critical Care Medicine, 2001
• The health economics of asthma and rhinitis. I. Assessing the economic impact
  Journal of Allergy and Clinical Immunology, 2001
• Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μ g twice daily and budesonide 800 μ g twice daily in the treatment of adults and adolescents with asthma
  Respiratory Medicine, 2000
• Risk factors and costs associated with an asthma attack
  Thorax, 2000
• Concurrent Use of Salmeterol with Inhaled Corticosteroids is More Effective than Inhaled Corticosteroid Dose Increases
  Allergy and Asthma Proceedings, 1999
• The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma
  Annals of Allergy, Asthma & Immunology, 1999
• Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
  New England Journal of Medicine, 1997
• Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
  American Journal of Respiratory and Critical Care Medicine, 1996
• Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
  The Lancet, 1994